Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

New Delhi Metallo-β-Lactamase-Producing Carbapenem-Resistant Enterobacteriacae Isolated From Bronchial Washings.

Cullivan S, Brady DM, O'Callaghan DS.

Ir Med J. 2017 Dec 18;110(10):663. No abstract available.

PMID:
29465853
2.

[Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin].

Boucly A, O'Connell C, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.

Presse Med. 2016 Jan;45(1):20-8. doi: 10.1016/j.lpm.2015.10.001. Epub 2015 Nov 4. French.

PMID:
26547673
3.

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

O'Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O'Donnell DM, Kay E, O'Connell F, Gallagher WM, O'Byrne KJ.

Eur Respir J. 2015 Dec;46(6):1762-72. doi: 10.1183/13993003.00176-2014. Epub 2015 Nov 5.

4.

Paraneoplastic limbic encephalitis and small-cell lung carcinoma.

Bolster F, Crosbie I, O'Callaghan DS, Murray B, Kavanagh EC.

J Thorac Oncol. 2015 May;10(5):852-3. doi: 10.1097/JTO.0000000000000386. No abstract available.

5.

Novel medical therapies for pulmonary arterial hypertension.

O'Connell C, O'Callaghan DS, Humbert M.

Clin Chest Med. 2013 Dec;34(4):867-80. doi: 10.1016/j.ccm.2013.08.002. Review.

PMID:
24267310
6.

An update on medical therapy for pulmonary arterial hypertension.

Wu Y, O'Callaghan DS, Humbert M.

Curr Hypertens Rep. 2013 Dec;15(6):614-22. Review.

PMID:
24122306
7.

Differentiating pulmonary cavities.

O'Connell C, Abdul Aziz M, O'Keane JC, Healy D, O'Callaghan DS.

Eur Respir Rev. 2013 Jun 1;22(128):191-2. doi: 10.1183/09059180.00005012. No abstract available.

8.

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.

Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, Devouassoux G, de Blay F, Couderc LJ, Didier A, O'Callaghan DS, Girodet PO, Bourdeix I, Le Gros V, Humbert M.

Chest. 2013 Aug;144(2):411-419. doi: 10.1378/chest.12-1961.

PMID:
23579324
9.

Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre.

Al-Alao BS, O'Callaghan DS, Gately K, Nicholson S, Coate LE, O'Connell F, McGovern E, O'Byrne KJ, Young VK.

Ir J Med Sci. 2013 Jun;182(2):217-25. doi: 10.1007/s11845-012-0863-0. Epub 2012 Nov 9.

PMID:
23139062
10.

A critical analysis of survival in pulmonary arterial hypertension.

O'Callaghan DS, Humbert M.

Eur Respir Rev. 2012 Sep 1;21(125):218-22. doi: 10.1183/09059180.00003512. Review.

11.

Renal replacement therapy in patients with severe precapillary pulmonary hypertension with acute right heart failure.

Sztrymf B, Prat D, Jacobs FM, Brivet FG, O'Callaghan DS, Price LC, Jais X, Sitbon O, Simonneau G, Humbert M.

Respiration. 2013;85(6):464-70. doi: 10.1159/000339346. Epub 2012 Aug 15.

12.

Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.

Savale L, Magnier R, Le Pavec J, Jaïs X, Montani D, O'Callaghan DS, Humbert M, Dingemanse J, Simonneau G, Sitbon O.

Eur Respir J. 2013 Jan;41(1):96-103. doi: 10.1183/09031936.00117511. Epub 2012 May 31.

13.

Portopulmonary hypertension: light at the end of the tunnel?

Sitbon O, O'Callaghan DS, Savale L.

Chest. 2012 Apr;141(4):840-842. doi: 10.1378/chest.11-2378. No abstract available.

PMID:
22474144
14.

Pulmonary arterial hypertension in patients treated by dasatinib.

Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M.

Circulation. 2012 May 1;125(17):2128-37. doi: 10.1161/CIRCULATIONAHA.111.079921. Epub 2012 Mar 26.

PMID:
22451584
15.

Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.

Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.

J Heart Lung Transplant. 2012 Feb;31(2):150-8. doi: 10.1016/j.healun.2011.11.002. Epub 2011 Dec 3.

PMID:
22138355
16.

Treatment of pulmonary arterial hypertension with targeted therapies.

O'Callaghan DS, Savale L, Montani D, Jaïs X, Sitbon O, Simonneau G, Humbert M.

Nat Rev Cardiol. 2011 Jul 19;8(9):526-38. doi: 10.1038/nrcardio.2011.104. Review.

PMID:
21769113
17.

The association between resting and mild-to-moderate exercise pulmonary artery pressure.

Whyte K, Hoette S, Herve P, Montani D, Jaïs X, Parent F, Savale L, Natali D, O'Callaghan DS, Garcia G, Sitbon O, Simonneau G, Humbert M, Chemla D.

Eur Respir J. 2012 Feb;39(2):313-8. doi: 10.1183/09031936.00019911. Epub 2011 Jul 7.

18.

A hemodynamic study of pulmonary hypertension in sickle cell disease.

Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, Maitre B, Yaïci A, Hajji L, O'Callaghan DS, Clerson P, Girot R, Galacteros F, Simonneau G.

N Engl J Med. 2011 Jul 7;365(1):44-53. doi: 10.1056/NEJMoa1005565.

19.

Pulmonary hypertension in patients with neurofibromatosis type I.

Montani D, Coulet F, Girerd B, Eyries M, Bergot E, Mal H, Biondi G, Dromer C, Hugues T, Marquette C, O'Connell C, O'Callaghan DS, Savale L, Jaïs X, Dorfmüller P, Begueret H, Bertoletti L, Sitbon O, Bellanné-Chantelot C, Zalcman G, Simonneau G, Humbert M, Soubrier F.

Medicine (Baltimore). 2011 May;90(3):201-11. doi: 10.1097/MD.0b013e31821be2b7.

20.

Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.

O'Callaghan DS, Savale L, Yaïci A, Natali D, Jaïs X, Parent F, Montani D, Humbert M, Simonneau G, Sitbon O.

Expert Opin Pharmacother. 2011 Jul;12(10):1585-96. doi: 10.1517/14656566.2011.564159. Epub 2011 Apr 20. Review.

PMID:
21504371
21.

Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?

O'Callaghan DS, Dorfmuller P, Jaïs X, Mouthon L, Sitbon O, Simonneau G, Humbert M, Montani D.

Presse Med. 2011 Jan;40(1 Pt 2):e65-78. doi: 10.1016/j.lpm.2010.10.017. Epub 2011 Jan 5. Review.

PMID:
21211937
22.

Current management approaches to portopulmonary hypertension.

Savale L, O'Callaghan DS, Magnier R, Le Pavec J, Hervé P, Jaïs X, Seferian A, Humbert M, Simonneau G, Sitbon O.

Int J Clin Pract Suppl. 2011 Jan;(169):11-8. doi: 10.1111/j.1742-1241.2010.02600.x. Review.

PMID:
21176011
23.

The role of inflammation in the pathogenesis of non-small cell lung cancer.

O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ.

J Thorac Oncol. 2010 Dec;5(12):2024-36. Review.

24.

Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre.

Montani D, O'Callaghan DS, Jaïs X, Savale L, Natali D, Redzepi A, Hoette S, Parent F, Sitbon O, Simonneau G, Humbert M.

Eur Respir Rev. 2009 Dec;18(114):272-90. doi: 10.1183/09059180.00005909. Review.

25.

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X, Parent F, Savale L, Natali D, Günther S, Chaouat A, Chabot F, Cordier JF, Habib G, Gressin V, Jing ZC, Souza R, Simonneau G; French Pulmonary Arterial Hypertension Network.

Eur Respir J. 2010 Sep;36(3):549-55. doi: 10.1183/09031936.00057010. Epub 2010 Jun 18.

26.

Pulmonary veno-occlusive disease: recent progress and current challenges.

Montani D, O'Callaghan DS, Savale L, Jaïs X, Yaïci A, Maitre S, Dorfmuller P, Sitbon O, Simonneau G, Humbert M.

Respir Med. 2010 Jul;104 Suppl 1:S23-32. doi: 10.1016/j.rmed.2010.03.014. Epub 2010 Apr 24. Review.

27.

Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension.

O'Callaghan DS, Savale L, Jaïs X, Natali D, Montani D, Humbert M, Simonneau G, Sitbon O.

Respir Med. 2010 Jul;104 Suppl 1:S74-80. doi: 10.1016/j.rmed.2010.03.020. Epub 2010 Apr 24. Review.

28.

Relief of chronic neuropathic pain through endothelin antagonism.

Murphy DM, O'Callaghan DS, Gaine SP.

Am J Med. 2010 Mar;123(3):e7. doi: 10.1016/j.amjmed.2009.07.025. No abstract available.

PMID:
20193818
29.

Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis.

Degano B, Sitbon O, Savale L, Garcia G, O'Callaghan DS, Jaïs X, Humbert M, Simonneau G.

Chest. 2010 Jun;137(6):1297-303. doi: 10.1378/chest.09-2060. Epub 2010 Jan 29.

PMID:
20118205
30.

Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.

Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jaïs X, Tregouet D, Reis A, Drouin-Garraud V, Fraisse A, Sitbon O, O'Callaghan DS, Simonneau G, Soubrier F, Humbert M.

Am J Respir Crit Care Med. 2010 Apr 15;181(8):851-61. doi: 10.1164/rccm.200908-1284OC. Epub 2010 Jan 7.

PMID:
20056902
31.

Angiosarcoma of the right atrium masquerading as recurrent pulmonary embolism.

O'Callaghan DS, Breen DP, Young V.

Thorac Cardiovasc Surg. 2008 Dec;56(8):488-90. doi: 10.1055/s-2007-989292. Epub 2008 Nov 14.

PMID:
19012217
32.

Pulmonary hypertension and left heart disease: emerging concepts and treatment strategies.

O'Callaghan DS, McNeil K.

Int J Clin Pract Suppl. 2008 Jul;(160):29-31. doi: 10.1111/j.1742-1241.2008.01819.x. Review.

PMID:
18638172
33.

Emerging treatments for pulmonary arterial hypertension.

O'Callaghan DS.

Clin Respir J. 2008 Jul;2(3):132-40. doi: 10.1111/j.1752-699X.2008.00059.x. Review.

PMID:
20298321
34.

From endothelial progenitor cells to vascular remodelling and more: 6 months in pulmonary hypertension.

Rich J, Thenappan T, Murphy D, O'Callaghan DS.

Int J Clin Pract Suppl. 2007 Dec;(158):26-36. doi: 10.1111/j.1742-1241.2007.01645.x. No abstract available.

PMID:
18078391
35.

Combination therapy and new types of agents for pulmonary arterial hypertension.

O'Callaghan DS, Gaine SP.

Clin Chest Med. 2007 Mar;28(1):169-85, ix. Review. Erratum in: Clin Chest Med. 2007 Jun;28(2):xi. O'Callaghan, Dermot [corrected to O'Callaghan, Dermot S].

PMID:
17338934
36.

Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.

O'Callaghan DS, Gaine SP.

Int J Clin Pract. 2006 Apr;60(4):475-81.

PMID:
16620363

Supplemental Content

Loading ...
Support Center